19479-83-5

Usage

Uses

Used in Scientific Research and Development:
1,1'-ethylenedipiperazine is used as a research compound for [application reason] in the field of organic chemistry. Its unique structure and properties make it a valuable tool for studying the behavior of piperazine derivatives and their potential applications in various chemical and biological processes.
Used in Pharmaceutical Development:
Although not extensively documented, 1,1'-ethylenedipiperazine may be used as a starting material or intermediate in the synthesis of pharmaceutical compounds. Its potential as a drug candidate or in the development of drug delivery systems could be explored due to its structural similarity to other piperazine-based drugs.
Used in Chemical Synthesis:
1,1'-ethylenedipiperazine may also be used as a building block in the synthesis of more complex organic molecules, particularly those involving piperazine rings. Its reactivity and functional groups could be exploited in the preparation of novel compounds with potential applications in various industries, such as materials science, agrochemistry, or specialty chemicals.

Upstream product

• 101433-80-1 4,4'-ethanediyl-bis-piperazine-1-carboxylic acid diethyl ester 
• 7542-23-6 piperazine hydrochloride 
• 106-93-4 ethylene dibromide 
• 110-85-0 piperazine 
• 6281-42-1 2-aminoethylimidazolidone 
• 107-06-2 1,2-dichloro-ethane 
• 2759-28-6 1-phenylmethylpiperazine 
• 158328-38-2 1,2-N,N'-bisethane 
• 107-15-3 ethylenediamine 
• 53502-60-6 1-(2-chloroethyl)-piperazine dihydrochloride 

Downstream Products

• 60013-06-1 1,2-Di-<1'-benzoyl-4-piperazinyl>-ethan 
• 77267-14-2 4,4'-dimethyl-1,1'-ethane-1,2-diyl-bis-piperazine 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of a novel series of bisintercalating DNA-binding piperazine-linked bisanthrapyrazole compounds as anticancer agents

A series of bisintercalating DNA binding bisanthrapyrazole compounds containing piperazine linkers were designed by molecular modeling and docking techniques. Because the anthrapyrazoles are not quinones they are unable to be reductively activated like doxorubicin and other anthracyclines and thus they should not be cardiotoxic. The concentration dependent increase in DNA melting temperature was used to determine the strength of DNA binding and the bisintercalation potential of the compounds. Compounds with more than a three-carbon linker that could span four DNA base pairs achieved bisintercalation. All of the bisanthrapyrazoles inhibited human erythroleukemic K562 cell growth in the low to submicromolar concentration range. They also strongly inhibited the decatenation activity of topoisomerase IIα and the relaxation activity of topoisomerase I. However, as measured by their ability to induce double strand breaks in plasmid DNA, the bisanthrapyrazole compounds did not act as topoisomerase IIα poisons. In conclusion, a novel group of bisanthrapyrazole compounds were designed, synthesized, and biologically evaluated as potential anticancer agents.

PROCESS FOR MANUFACTURING ALKYLENEAMINE COMPOUNDS

The invention pertains to a process for manufacturing alkyleneamine compounds, comprising the steps of - in a reaction medium reacting an alkyleneurea compound comprising at least one primary amine group, or at least one cyclic secondary amine group, or at least one primary amine group and at least one cyclic secondary amine group, and at least one cyclic alkyleneurea group of formula I wherein A is selected from the group of C2 to C4 alkylene units, optionally substituted by one or more C1 to C3 alkyl groups, with an alkylhalide compound to form an alkyleneamine hydrohalide salt comprising at least one cyclic alkyleneurea group of formula I, the alkylhalide compound being selected from the group of haloalkanes with 2-6 halogen atoms, and haloaminoalkanes, and - reacting the alkyleneamine hydrohalide salt with a base to form an alkyleneamine compound comprising at least one cyclic alkyleneurea group of formula I. In one embodiment the reaction is carried out in the presence of one or more of ammonia and additional alkyleneamine compound. The process according to the invention produces less cyclic and branched side products and more straight-chain higher alkyleneamines than conventional processes, in particular more straight-chain ethyleneamines selected from L-TETA, L-TEPA, and L-PEHA. The formula I is represented herein.

PROCESS FOR MANUFACTURING ALKYLENEAMINE COMPOUNDS

The invention pertains to a process for manufacturing alkyleneamine compounds, comprising the steps of - in a reaction medium reacting an alkyleneurea compound comprising at least one primary amine group, or at least one cyclic secondary amine group, or at least one primary amine group and at least one cyclic secondary amine group, and at least one cyclic alkyleneurea group of formula I wherein A is selected from the group of C2 to C4 alkylene units, optionally substituted by one or more C1 to C3 alkyl groups, with an alkylhalide compound to form an alkyleneamine hydrohalide salt comprising at least one cyclic alkyleneurea group of formula I, the alkylhalide compound being selected from the group of haloalkanes with 2-6 halogen atoms, and haloaminoalkanes, and - reacting the alkyleneamine hydrohalide salt with a base to form an alkyleneamine compound comprising at least one cyclic alkyleneurea group of formula I. In one embodiment the reaction is carried out in the presence of one or more of ammonia and additional alkyleneamine compound. The process according to the invention produces less cyclic and branched side products and more straight-chain higher alkyleneamines than conventional processes, in particular more straight-chain ethyleneamines selected from L-TETA, L-TEPA, and L-PEHA.

Double-component diazeniumdiolate derivatives as anti-cancer agents

In this study, we synthesized a series of double-component O2-aryl diazeniumdiolate (DDNO) derivatives, of which each molecule can release up to four nitric oxide molecules. These compounds showed cytotoxic activities to cancer cells, such as human leukemia, breast cancer and lung cancer. Among them, compound 1 (DDNO-1) showed the highest specific activity to human leukemia cells. It induced cell apopotosis and arrest cell cycle of G2/M phase. The JNK and p38 protein kinases were activated by compound 1 to induce cancer cell apoptosis. Compound 1 also increased pro-apoptotic Bax level, which is a same function compared to a reported NO donor, JS-K. More interestingly, it decreased the level of an anti-apoptotic member Bcl-2, which is an opposite effect compared to JS-K. Compound 1 could be developed as a new anti-cancer agent since it increases the Bax/Bcl-2 ratio to overcome the drug resistance.

BIS-DIAZENIUMDIOLATE COMPOUNDS AS ANTI-CANCER AGENTS

A series of double-component, bis O2-aryl diazeniumdiolate derivatives are provided, of which each molecule can release up to four nitric oxide molecules. These compounds show cytotoxic activities to cancer cells, such as human leukemia, breast cancer and lung cancer. Among them, the compound 3 showed the highest specific activity against human leukemia cells.

COMPOUNDS CONTAINING MORE THAN ONE HUMAN NEUTROPHIL ELASTASE INHIBITING MOIETY FOR USE IN THE TREATMENT OF RESPIRATORY DISEASES

A compound of formula (I) (M)-(L)-(M) or formula (IV) [(M)-(L)t]-G: wherein each M is independently an inhibitor of HNE; each L is independently a linker group; t is 2 to 20; G is aryl, heteroaryl, alkyl, cycloalkyl, nitrogen, a dendrimer or a group of any of formulae (V) to (VII): wherein Ar is aryl or heteroaryl; and u is 2 to 20; or a pharmaceutically acceptable salt, solvate, N-oxide or prodrug thereof.

DIHYDROPYRIMIDONE MULTIMERS AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS

A compound of formula M-L-M (I) wherein L is a linker and each M is independently a group of formula (II) is useful in therapy, e.g. of respiratory diseases.

Synthesis of Bis-piperazine-type pH Buffer Agents and Their Application to Mammalian Cell Cultures

New bis-piperazine-type pH buffer agents were synthesized and their buffering properties were evaluated.The compounds proved to have two-fold larger pH buffering ability than 2-ethanesulfonic acid (HEPES), a Good's buffer traditionally used to control the pH value of culture media.Human-human hybridoma HB4C5 cells were cultured in a serum-free medium containing these buffer agents.The cell growth and antibody production, using 1,2-N,N'-bisethane, were greater than when HEPES.

Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol

Bivalent ligand compounds synthesized from a tether composition joining two heterocyclic groups comprising furochromones, furobenzoxazinones, and benzobisdifurans. These compounds show pharmacological activity in blocking ACAT enzymes which are major regulators of cholesterol metabolism. The compounds also show activity in lowering plasma triglycerides and elevating HDL cholesterol. They are useful in the prevention or treatment of the constriction or obstruction of arterial vessels, atherosclerosis, hyperlipidemia, hypertriglyceridemia, chylomicronemia, and pancreatitis.